PubMed Health⌕ Search

Biomedical subjects

S H Hohnloser

Publications and source records attributed to S H Hohnloser.

At least 55 records · Page 3Linked to original sources
PubMed2000

Location of the lower turnaround point in typical AV nodal reentrant tachycardia: a quantitative model.

INTRODUCTION: Recent observations suggest that the circuit of AV nodal reentrant tachycardia (AVNRT) may extend down to the His bundle. The purpose of this study was to develop a quantitative model indicating the location of the lower turnaround point in AVNRT. METHODS AND RESULTS: Slow pathway modification was performed in 70 patients with typical AVNRT. During sinus rhythm, ventricular pacing was performed with the AVNRT cycle length. During AVNRT, the HinitAinit interval was measured from initial His to the initial atrial deflection recorded in the His-bundle lead. During ventricular pacing, the HendAinit interval was measured from end of the His to the beginning of the atrial deflection. It was hypothesized that x reflects conduction time from the lower turnaround point to Ainit, whereas y reflects conduction time from the lower turnaround point to Hinit. Anterograde conduction during AVNRT and retrograde conduction during ventricular pacing were assumed to be identical if there was 1:1 retrograde conduction at the AVNRT cycle length. The following formulas describe the relation of the measured parameters: x - y = HinitAinit; and x + y = HendAinit. Resolving both formulas yields the unknown x and y: y = (HendAinit - HinitAinit)/2, x = (HendAinit + HinitAinit)/2. These criteria were present in 52 of 70 patients. The mean cycle length of AVNRT was 355 +/- 42 msec, mean HinitAinit was 54 +/- 27 msec, and mean HendAinit was 60 +/- 29 msec. Accordingly, in 20 of 52 patients, the lower turnaround point was located within the His bundle (y = -15.4 +/- 16.1 msec), in 3 of 52 it was in the nodal-His junctional area (y = 0), and in 29 of 52 it was above the His bundle (y = +12.7 +/- 10.3 msec). The HinitAinit interval was significantly longer (66 +/- 32 msec vs 47 +/- 20 msec; P = 0.02) and the HendAinit interval was significantly shorter (45 +/- 30 msec vs 69 +/- 24 msec; P = 0.004) when the first group was compared with the others. CONCLUSION: In about 1 of 3 of patients with typical AVNRT, the lower turnaround point of the circuit is within the His bundle; in more than half of the patients it is above the His bundle. These data do not support the concept that all AVNRTs have an intranodal circuit, but are in accordance with the finding of longitudinal dissociation of the His bundle.

Adult↗
PubMed2000

Pharmacological management of atrial fibrillation: an update.

Therapy of atrial fibrillation remains difficult in many patients. There is increasing awareness that antiarrhythmic drug therapy instituted to maintain sinus rhythm after successful cardioversion of atrial fibrillation may pose a substantial risk to the patient. Therefore, results of prospective randomized trials are needed to allow a more evidence-based approach to the treatment of this common arrhythmia. Two recently published studies have shown superiority of amiodarone over conventional antiarrhythmic drugs in maintaining sinus rhythm. The largest such study published today, the Canadian Trial in Atrial Fibrillation (CTAF), has randomized 403 patients to amiodarone or to sotalol or propafenone. At the end of the observation period, amiodarone-treated patients were significantly more likely to remain in sinus rhythm than conventionally treated patients. A number of new antiarrhythmic drugs, mainly class III substances, are currently developed for the treatment of atrial fibrillation or atrial flutter. Ibutilide has recently been released for intravenous administration, attempting pharmacological cardioversion of atrial fibrillation/atrial flutter. It has been evaluated in a number of prospective trials, which showed a higher conversion rate in patients with atrial flutter. Dofetilide is another new compound developed mainly for maintenance of sinus rhythm after restoration of sinus rhythm. It has been evaluated in two prospective, randomized, placebo-controlled trials; moreover, analysis of the DIAMOND trials showed effectiveness of dofetilide in maintaining sinus rhythm in patients with depressed left ventricular function without increased mortality when compared with placebo. Finally, several ongoing studies compare the therapeutic strategy of controlling ventricular rate in atrial fibrillation compared with the strategy of maintaining sinus rhythm. These trials will help to optimize therapy in atrial fibrillation, the most commonly encountered arrhythmia.

Anti-Arrhythmia Agents↗
PubMed2000

[Microvolt level T wave alternans: a new marker for noninvasive risk stratification].

Prospective identification of patients with structural heart disease who could profit from prophylactic ICD therapy is hampered by the low predictive power of the currently available risk stratification parameters. Microvolt T wave alternans measured noninvasively is a new promising parameter to assess impaired ventricular repolarization which has been associated with an increased incidence of ventricular tachyarrhythmias. T wave alternans is rate-dependent; to induce alternans, heart rate may be increased by atrial stimulation during invasive EP testing or noninvasively by exercise stress testing. The first clinical validation with respect to prediction of inducibility of ventricular tachyarrhythmias and of arrhythmic events during follow-up in patients undergoing invasive EP testing was reported in 1994. Subsequently, a good concordance between the results of invasive and noninvasive assessment of T wave alternans was demonstrated by our group. The first prospective evaluation of the noninvasive alternans measurement using submaximal exercise testing was performed in patients surviving prehospital ventricular fibrillation or sustained ventricular tachycardia referred to our institution. The occurrence of T wave alternans in this patient population was predictive of future tachyarrhythmic events with subsequent appropriate ICD therapy. The results of the currently performed prospective trials in various patient populations will help to establish the utility of T wave alternans assessment as a risk stratifier in clinical practice.

Action Potentials↗
PubMed1999

Implantable devices versus antiarrhythmic drug therapy in recurrent ventricular tachycardia and ventricular fibrillation.

The implantable cardioverter defibrillator (ICD) protects patients from sudden cardiac death due to ventricular tachyarrhythmias. The capability of an improved overall survival of high-risk patients in comparison to the best pharmacologic therapy has been evaluated over the last few years in prospective randomized trials. In patients with a history of resuscitated ventricular fibrillation (VF) or unstable ventricular tachycardia (VT), the ICD was superior to therapy with amiodarone in 3 large trials involving 2,024 patients. At 2-year follow-up, ICD therapy was associated with a relative reduction in the risk of death of 20% to 30%. With respect to primary prevention of arrhythmogenic death, data are less convincing. The Multicenter Automatic Implantable Defibrillator (MADIT) study proved superiority of ICD therapy over medical treatment in coronary patients with depressed left ventricular function, nonsustained VT, and inducible but not suppressible sustained VT/VF. The second trial, the Coronary Artery Bypass Graft (CABG)-Patch trial, failed to show a similar superiority in 900 patients with an ejection fraction of < or = 35% and an abnormal signal-averaged electrocardiograph undergoing coronary artery bypass grafting. Thus, the role of device therapy for primary prevention of sudden death has not been established. Future prospective studies are needed to clarify this issue.

Amiodarone↗
PubMed1999

Septal Q waves in surface electrocardiographic lead V6 exclude minimal ventricular preexcitation.

Electrocardiograms of 37 consecutive patients with minimal preexcitation (i.e., PR >120 ms, QRS <120 ms) were compared before and after ablation with electrocardiograms of 37 age-matched patients with atrioventricular nodal reentrant tachycardia. The presence of a septal Q wave could be used to exclude minimal preexcitation with a high degree of reliability in both patients and controls before and after radiofrequency ablation.

Cardiac Pacing, Artificial↗
PubMed1999

Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group.

BACKGROUND: Patients with implantable cardioverter-defibrillators often receive adjunctive antiarrhythmic therapy to prevent frequent shocks. We tested the efficacy and safety of sotalol, a beta-blocker with class III antiarrhythmic effects, for this purpose. METHODS: In a multicenter trial, patients were stratified according to left ventricular ejection fraction (< or =0.30 or >0.30), randomly assigned to double-blind treatment with 160 to 320 mg of sotalol per day (151 patients) or matching placebo (151 patients), and followed for 12 months. Kaplan-Meier analyses of the time to an event were performed. Three end points were used: the delivery of a first shock for any reason or death from any cause, the first appropriate shock for a ventricular arrhythmia or death from any cause, and the first inappropriate shock for a supraventricular arrhythmia or death from any cause. RESULTS: Compliance with double-blind treatment was similar in the two groups. There were seven deaths in the placebo group and four in the sotalol group. As compared with placebo, treatment with sotalol was associated with a lower risk of death from any cause or the delivery of a first shock for any reason (reduction in risk, 48 percent; P<0.001 by the log-rank test), death from any cause or the delivery of a first appropriate shock (reduction in risk, 44 percent; P=0.007), or death from any cause or the delivery of a first inappropriate shock (reduction in risk, 64 percent; P=0.004). Sotalol also reduced the mean (+/-SD) frequency of shocks due to any cause (1.43+/-3.53 shocks per year, as compared with 3.89+/-10.65 in the placebo group; P=0.008). In the sotalol group, the reduction in the risk of death from any cause or the delivery of a first shock for any reason did not differ significantly between patients with ejection fractions of more than 0.30 and those with ejection fractions of 0.30 or less. CONCLUSIONS: Oral sotalol was safe and efficacious in reducing the risk of death or the delivery of a first defibrillator shock whether or not ventricular function was depressed.

Adrenergic beta-Antagonists↗
PubMed1999

[Cardiac autonomic tone in risk stratification after myocardial infarct: results of a prospective long-term study of 411 consecutive patients].

Prognosis of patients surviving acute myocardial infarction has substantially improved over the last two decades. However, stratification of patients at risk for death due to arrhythmic events remains a clinical challenge. Due to the important role of the autonomic nervous system in the genesis of sudden death, autonomic markers such as heart rate variability and baroreflex sensitivity have recently gained attention as risk stratification parameters. The present study reports the results of noninvasive risk stratification in 411 consecutive postinfarction patients treated due to contemporary therapeutical guidelines with a high proportion of patients discharged with a patent infarct related artery. The diagnostic arsenal of risk parameters comprised heart rate variability, baroreflex sensitivity, and more traditional markers such as non-sustained ventricular tachycardia, left ventricular ejection fraction, and ventricular late potentials. Patients were followed for a mean of 33 +/- 21 months. Stepwise logistic regression analysis revealed that left ventricular function, both autonomic markers, and the patency of the infarct related artery were independent predictors of the prospectively defined primary study endpoint, i.e., all-cause mortality plus ventricular tachyarrhythmic events. With respect to the secondary endpoint (ventricular tachyarrhythmic events), left ventricular function, heart rate variability, and infarct vessel patency were independent predictors. Ventricular late potentials and nonsustained ventricular tachycardia had no predictive value with respect to ventricular tachyarrhythmic events. These findings from a large prospective long-term study demonstrate the value of markers of cardiac autonomic tone in identifying infarct survivors at risk for malignant ventricular tachyarrhythmias and sudden death.

Adult↗
PubMed1999

[T-wave alternans in microwave frequency as a new indicator of disordered ventricular repolarization: pathophysiology, methodology, clinical results].

Primary prevention of sudden cardiac death is hampered by the inability to accurately identify high risk patients. Various noninvasive methods such as determination of left ventricular function or heart rate variability as well as invasive electrophysiologic testing are currently used for risk stratification. Noninvasive measurement of microvolt T wave alternans (TWA) is a promising new method to assess repolarization abnormalities; in experimental studies, TWA was associated with an increased incidence of ventricular tachyarrhythmias. Since the occurrence of TWA is heart rate-dependent, it is measured either during atrial pacing or during exercise stress testing. The first clinical validation of the method was performed in patients undergoing invasive EP testing to assess prediction of inducibility of ventricular tachyarrhythmias. A first prospective validation of the noninvasive method was performed in patients surviving out-of-hospital cardiac arrest fitted with an ICD. Further studies have shown a good concordance between invasive and noninvasive TWA determination. The occurrence of TWA in this population was of predictive value with respect to arrhythmia recurrence. Recently published data confirm the value of TWA assessment with respect to identification of patients with congestive heart failure at high risk of malignant ventricular tachyarrhythmias. The use of this method in post myocardial infarction risk stratification is currently under prospective evaluation.

Cardiac Pacing, Artificial↗
PubMed1999

QT dispersion in exercise-induced myocardial hypertrophy.

BACKGROUND: The measurement of QT dispersion in the surface electrocardiogram is a noninvasive method used for assessing inhomogeneity of myocardial repolarization. Elevated QT dispersion is found in myocardial disease and is associated with an increased incidence of arrhythmic events. QT dispersion is also increased in myocardial hypertrophy secondary to systemic hypertension. However, the relation between left ventricular (LV) enlargement in endurance trained subjects and QT dispersion is unknown. METHODS AND RESULTS: In this study, LV mass (2-dimensional echocardiography) and QT dispersion (12-lead resting electrocardiogram) were assessed in 26 normotensive endurance trained subjects and 26 matched, less trained control subjects. Endurance trained subjects had a significantly greater LV mass (216 +/- 39 g vs 155 +/- 30 g, P <.001) but lower heart rate-corrected QTc dispersion (42 +/- 13 ms vs 51 +/- 15 ms, P =.012) than less trained control subjects. When all individuals were included, LV mass was inversely correlated with QT dispersion (r = -0.38; P =.002) and heart rate-corrected QTc dispersion (r = -0.53, P <.0001). CONCLUSIONS: These data show that myocardial hypertrophy induced by exercise training is not associated with increased QT dispersion as observed in systemic hypertension. The reduced QT dispersion reflects homogeneous myocardial repolarization and may help to explain the reduced mortality rate in regularly exercising subjects. If confirmed in further studies, the measurement of QT dispersion could provide a simple and inexpensive screening method for differentiating between physiologic and pathologic myocardial hypertrophy.

Adolescent↗
PubMed1999

Prevalence, characteristics and prognostic value during long-term follow-up of nonsustained ventricular tachycardia after myocardial infarction in the thrombolytic era.

OBJECTIVES: The purpose of this study was to determine the prevalence, characteristics and the predictive value of nonsustained ventricular tachycardia (VT) for subsequent death and arrhythmic events after acute myocardial infarction (AMI). BACKGROUND: Nonsustained VT has been linked to an increased risk for sudden death in coronary patients. It is unknown whether this parameter can be used for selection of high-risk patients to receive an implantable defibrillator for primary prevention of sudden death in patients shortly after AMI. METHODS: In 325 consecutive infarct survivors, 24-h Holter monitoring was performed 10+/-6 days after AMI. All patients underwent coronary angiography, determination of left ventricular function and assessment of heart rate variability (HRV). Mean follow-up was 30+/-22 months. RESULTS: There was a low prevalence (9%) of nonsustained VT shortly after AMI. Nonsustained VT together with depressed left ventricular ejection fraction (LVEF) was found in only 2.4% of patients. During follow-up, 25 patients reached one of the prospectively defined end points (primary composite end point of cardiac death, sustained VT or resuscitated ventricular fibrillation; secondary end point: arrhythmic events). Kaplan Meier event probability analyses revealed that only HRV, LVEF and status of the infarct-related artery were univariate predictors of death or arrhythmic events. The presence of nonsustained VT carried a relative risk of 2.6 for the primary study end point but was not a significant predictor if only arrhythmic events were considered. On multivariate analysis, only HRV, LVEF and the status of the infarct artery were found to be independently related to the primary study end point. CONCLUSIONS: There is a low prevalence of nonsustained VT shortly after AMI. Only 2% to 3% of all infarct survivors treated according to contemporary guidelines demonstrate both depressed LVEF and nonsustained VT. The predictive value of nonsustained VT for subsequent mortality and arrhythmic events is inferior to that of impaired autonomic tone, LVEF or infarct-related artery patency. Accordingly, the use of nonsustained VT to select patients for primary implantable cardioverter/defibrillator prevention trials shortly after AMI appears to be limited.

Adult↗
PubMed1999

First worldwide clinical experience with a new dual chamber implantable cardioverter defibrillator. Advantages and complications. The Ventak AV II DR investigators.

AIMS: The need for physiological pacing and for improving the ability to discriminate atrial from ventricular tachyarrhythmias has prompted the development of dual chamber implantable cardioverter/defibrillators (ICDs). METHODS: Fifty-two patients were implanted with a newly developed dual-chamber ICD providing rate-responsive physiological pacing (Ventak AV II DR). The device possesses two new arrhythmia detection algorithms ('atrial fibrillation rate threshold' and 'ventricular to atrial rate relationship') in addition to commonly used features such as 'onset' and 'stability'. During implantation, the atrial and ventricular lead impedances and pacing thresholds were determined together with the defibrillation threshold. Prior to discharge, attempts were made to induce both atrial and ventricular tachyarrhythmias in order to test those new detection criteria. All patients were followed for at least 3 months. RESULTS: The device was successfully implanted in all 52 patients. Placement of the atrial lead was successful in 50/52 patients (96%; P-wave 3.2 +/- 1.4 mV; impedance 576 +/- 123 omega; atrial pacing threshold 1.2 +/- 0.9 V). Prior to discharge, 32 episodes of atrial fibrillation (AF) alone, 38 episodes of AF with ventricular fibrillation and 10 episodes of AF with monomorphic ventricular tachycardia were induced in 33/50 patients (66%) and all were appropriately classified by the detection algorithm. During the 3 months follow-up, 12 patients (23%) had appropriate and successful therapies for ventricular arrhythmias, while four patients (8%) experienced inappropriate ICD therapies. Although all these episodes were detected correctly as supraventricular arrhythmias by the device, therapy was delivered because of incorrect or incomplete programming. In all cases reprogramming of the device resolved the problem. CONCLUSION: Implantation of dual chamber ICDs is feasible and appears to improve discrimination of supraventricular from ventricular tachyarrhythmias. In addition, patients with tachyarrhythmias and concomitant bradyarrhythmias may benefit from simultaneous physiological pacing. However, implantation and follow-up of such patients should be performed at experienced centres since both surgical handling and programming of these devices is more difficult and complex than conventional ICDs.

Algorithms↗
PubMed1999

Atrial flutter in the recipient atrium induced by premature beats arising from the donor atrium 10 years after orthotopic heart transplantation.

BACKGROUND: Several mechanisms for the genesis of supraventricular arrhythmias in patients after orthotopic heart transplantation have been reported. METHODS AND RESULTS: We describe a 58-year-old male patient in whom atrial flutter occurred 10 years after orthotopic heart transplantation. During an electrophysiological study, bidirectional conduction between the recipient and donor atria was found. Atrial flutter in the recipient atrium was induced by programmed stimulation of the donor atrium using a single extrastimulus. The clinical symptoms were caused by atrial flutter arising from the recipient atrium with 1:1 to 3:1 conduction to the donor atrium. Mapping the anastomosis between the two atria indicated fragmented potentials at a discrete site of conduction. Delivery of radiofrequency energy at this site terminated conduction in both directions. Subsequent atrial pacing of the donor and recipient atria, respectively, demonstrated bidirectional conduction block. CONCLUSION: Symptomatic arrhythmias in patients after heart transplantation can indirectly originate from the donor atrium via bidirectional recipient-donor atrial conduction. This type of arrhythmia can be successfully treated with radiofrequency ablation.

Atrial Flutter↗
PubMed1999

Pharmacological therapy of atrial fibrillation.

Pharmacological treatment of atrial fibrillation aims at reducing symptoms and possible complications of this frequently encountered arrhythmia. Prevention of embolic events by means of oral vitamin K antagonists is therefore mandatory in most patients presenting with atrial fibrillation. Whereas in paroxysmal atrial fibrillation reduction in frequency and duration of episodes is the treatment goal, symptomatic relief of persistent atrial fibrillation can be achieved by two treatment strategies: 1) restoration of sinus rhythm, referred to as rhythm control, and 2) limitation of the average and maximal ventricular heart rate, referred to as rate control. This review provides data from relevant clinical studies addressing the effectiveness and limitations of currently available drug therapy according to the two treatment approaches.

Anti-Arrhythmia Agents↗
PubMed1999

Prospective evaluation of a two-step therapeutic strategy in neurocardiogenic syncope: midodrine as second line treatment in patients refractory to beta-blockers.

Pharmacological therapy of neurocardiogenic syncope is often limited by the relatively low response rate to such treatment. In particular, response to beta-blocker treatment has been reported to average 50%. Therefore, a two-step protocol, with metoprolol being the drug of first choice, was developed and prospectively evaluated in consecutive patients with a history of repeated syncopal attacks and a positive tilt table test indicative of neurocardiogenic syncope. Patients not responding to the beta-blocker were switched to the alpha-adrenoceptoragonist midodrine. Acute drug efficacy was assessed by repeated tilt table testing. The incidence of syncope recurrence rate was determined during a 7-month follow-up. In 16 of 30 (53%) patients, metoprolol was primarily effective; this was also the case in 7 of 11 patients receiving midodrine. Thus, the overall efficacy rate could be increased to 77% by the treatment protocol (P = 0.009, as compared to beta-blocker treatment alone). During follow-up, only 1 of 27 patients (4%) had a syncopal event. Thus, the two-step treatment protocol presented in this study proved to be safe and to improve significantly patients clinical symptoms, as well as results of repeated tilt table testing as compared to beta-blocker treatment alone.

Adrenergic alpha-Agonists↗
PubMed1999

Clinical value of the postpacing interval for mapping of ventricular tachycardia in patients with prior myocardial infarction.

INTRODUCTION: The postpacing interval (PPI) has been used to discriminate bystander sites from critical sites within a ventricular tachycardia (VT) reentry circuit, with a PPI that is similar to the VT cycle length (CL) being indicative of a site within the reentry circuit. The purpose of this study was to assess the clinical value of the PPI for identifying effective target sites for ablation of VT at sites of concealed entrainment in patients with prior myocardial infarction. METHODS AND RESULTS: In 24 patients with coronary artery disease and a past history of myocardial infarction, 36 VTs with a mean CL of 483+/-80 msec (+/- SD) were mapped and targeted for radiofrequency (RF) ablation. The only criterion used to select target sites for ablation was concealed entrainment. In a post hoc analysis, the PPI was measured at 47 ineffective and 26 effective ablation sites. The mean PPI-VTCL difference at the 26 effective sites (114+/-137 msec) did not differ significantly from the mean at the 47 ineffective sites (177+/-161 msec; P = 0.1). The sensitivity of a PPI-VTCL difference < or = 30 msec for identifying an effective ablation site was 46%, the specificity 64%, the positive predictive value 41%, and the negative predictive value 68%. CONCLUSION: The PPI-VTCL difference is not useful for discriminating between sites of concealed entrainment that are within or outside of a VT reentry circuit in patients with prior infarction. Therefore, in patients with prior infarction, the PPI is not clinically useful for identifying sites of concealed entrainment at which RF ablation should or should not be attempted.

Aged↗
PubMed1999

Discrete systolic potentials during ventricular tachycardia in patients with prior myocardial infarction.

INTRODUCTION: Isolated diastolic potentials have been found to be helpful in identifying critical sites for ablation of ventricular tachycardia (VT) in patients with coronary artery disease. However, discrete potentials that occur during systole have not been previously described. The purpose of this study was to determine the significance of discrete systolic potentials during VT in patients with coronary artery disease. METHODS AND RESULTS: Twenty-seven patients with a mean age of 66 +/- 12 years ( +/- standard deviation) who had coronary artery disease underwent radiofrequency catheter ablation of 42 VTs that had a mean cycle length of 486 +/- 78 msec. The only criterion used to select target sites for ablation was concealed entrainment, which was present at 92 sites. Thirty-five of the 42 VTs (83%) were successfully ablated. A discrete systolic potential was recorded during 7 of the 42 VTs (17%). In all cases, the interval between the discrete systolic potential and the next QRS complex was equal to the stimulus-QRS interval during concealed entrainment. At all seven sites where a discrete systolic potential was recorded, delivery of radiofrequency energy resulted in successful ablation of the VT. CONCLUSION: Discrete systolic potentials may be present in patients with coronary artery disease in approximately 17% of VTs in which there is concealed entrainment. If the interval between the discrete systolic potential and the next QRS complex matches the stimulus-QRS interval during concealed entrainment, delivery of radiofrequency energy is likely to result in successful ablation of the VT.

Action Potentials↗